ESSENTIALS OF DIAGNOSIS
Women: copious vaginal discharge.
Men: nongonococcal urethritis.
Motile trichomonads on wet mounts.
Trichomoniasis is caused by the protozoan Trichomonas vaginalis and is among the most common sexually transmitted diseases, causing vaginitis in women and nongonococcal urethritis in men. It can also occasionally be acquired by other means, since it can survive in moist environments for several hours.
T vaginalis is often harbored asymptomatically. For women with symptomatic disease, after an incubation period of 5 days to 4 weeks, a vaginal discharge develops, often with vulvovaginal discomfort, pruritus, dysuria, dyspareunia, or abdominal pain. Examination shows a copious discharge, which is usually not foul smelling but is often frothy and yellow or green in color. Inflammation of the vaginal walls and cervix with punctate hemorrhages are common. Most men infected with T vaginalis are asymptomatic, but it can be isolated from about 10% of men with nongonococcal urethritis. In men with trichomonal urethritis, the urethral discharge is generally more scanty than with other causes of urethritis.
Diagnosis is traditionally made by identifying the organism in vaginal or urethral secretions. Examination of wet mounts will show motile organisms. Tests for bacterial vaginosis (pH > 4.5, fishy odor after addition of potassium hydroxide) are often positive with trichomoniasis. Newer point-of-care antigen detection and nucleic acid probe hybridization tests and nucleic acid amplification assays offer improved sensitivity compared to wet mount microscopy and excellent specificity.
The treatment of choice is tinidazole or metronidazole, each as a 2 g single oral dose. Tinidazole may be better tolerated and active against some resistant parasites. Toxicities of these drugs are discussed in the section on amebiasis. If the large single dose cannot be tolerated, an alternative metronidazole dosage is 500 mg orally twice daily for 1 week. A meta-analysis suggested that multiple dose regimens offer improved efficacy, although this is not standard. All infected persons should be treated, even if asymptomatic, to prevent subsequent symptomatic disease and limit spread. Treatment failure suggests reinfection, but metronidazole-resistant organisms have been reported. These may be treated with tinidazole, longer courses of metronidazole, intravaginal paromomycin, or other experimental therapies (see Chapter 18-05).
et al. Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis
in women and men. Sex Transm Infect. 2017 Dec;93(S4):S31–5.
et al. Modern diagnosis of Trichomonas vaginalis
infection. Sex Transm Infect. 2013 Sep;89(6):434–8.
et al. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. Sex Transm Dis. 2017 Jan;44(1):29–34.
et al. A review of evidence-based care of symptomatic trichomoniasis ...